NTLA
Intellia Therapeutics Inc
12.70$
+3.8%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 184.8% | 193.2% | 259.0% | 292.8% | 251.5% | 259.4% | 20.8% | 14.5% | 24.7% | 17.8% | 23.5% | |
| – | -84.8% | 100.0% | 100.0% | 100.0% | -151.5% | 100.0% | 100.0% | 85.5% | 75.3% | 82.2% | 76.5% | |
| – | 184.8% | 193.2% | 259.0% | 292.8% | 251.5% | 259.4% | 695.3% | 805.8% | 1,199.4% | 805.7% | 574.6% | |
| – | 137.0% | 101.9% | 107.3% | 105.8% | 95.3% | 76.2% | 215.1% | 173.3% | 321.1% | 217.4% | 177.0% | |
| – | 321.9% | 295.2% | 366.3% | 398.6% | 95.3% | 335.5% | 910.4% | 964.5% | 1,495.8% | 1,005.3% | 728.1% | |
| – | -221.9% | -195.2% | -266.3% | -298.6% | -246.8% | -235.5% | -810.4% | -879.0% | -1,420.5% | -923.1% | -651.7% | |
| – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 4.1% | 20.8% | 16.4% | – | – | – | |
| – | -221.9% | -192.0% | -258.6% | -280.4% | -230.9% | -231.5% | -810.5% | -909.8% | -1,326.5% | -896.8% | -609.9% | |
| – | -16.7% | -6.7% | -11.5% | 18.2% | -15.9% | -14.9% | -24.7% | 30.7% | -137.1% | – | – | |
| – | -205.1% | -192.0% | -258.6% | -280.4% | -230.9% | -216.5% | -785.8% | -909.8% | -1,326.5% | -896.8% | -609.9% | |
| – | -216.4% | -188.5% | -254.9% | -283.9% | -233.8% | -224.6% | -789.5% | -895.3% | -1,301.8% | -879.0% | -586.3% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.